PRN: Liver Cancer in 18 Major Markets 2017-2027: USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China, Turkey, Mexico, Russia, Argentina, Australia, Saudi Arabia and South Africa - Research and Markets

03/mar/2017 11:15:11 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Liver Cancer in 18 Major Markets 2017-2027: USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China, Turkey, Mexico, Russia, Argentina, Australia, Saudi Arabia and South Africa - Research and Markets

 
[03-March-2017]
 

DUBLIN, Mar 3, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Liver Cancer Forecast in 18 Major Markets 2017-2027" report to their offering.

Liver Cancer, also known as hepatic cancer or primary liver cancer, is a cancer which starts in the cells of the liver. The most common form is hepatocellular carcinoma (HCC) which originates from hepatocytes, the most abundant cell type in the liver, although other cell types in the liver can also become cancerous.

This report provides the current incident population for Liver Cancer across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China, Turkey, Mexico, Russia, Argentina, Australia, Saudi Arabia and South Africa) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along ! with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Liver Cancer have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Liver Cancer include:

- Type 2 Diabetes Mellitus

- Liver Cirrhosis

- Hepatitis C

- Hepatitis B

Key Topics Covered:

1. Introduction

2. Cause of the Disease

3. Risk Factors & Prevention

4. Diagnosis of the Disease

5. Variation by Geography/Ethnicity

6. Disease Prognosis & Clinical Course

7. Key comorbid conditions/features associated with the disease

8. Methodology for quantification of patient numbers

9. Top-line estimated incidence for Liver Cancer

10. Features of Liver Cancer patients

11. Abbreviations used in the report

12. Patient-Based Offering

13. Online Pricing Data and Platforms

14. References

15. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/lk65xj/liver_cancer

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

 

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl